SCHEMBL2910353

SCHEMBL2910353

Nc1nc(N)c2c(-c3ccco3)n[nH]c2n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 12/20 0.55
ADORA1 P30542 9/20 0.55
DHFR P00374 1/20 0.51
MEN1 O00255 3/20 0.44
ALDH1A1 P00352 3/20 0.44
POLB P06746 3/20 0.44
MAPT P10636 3/20 0.44
PKM P14618 3/20 0.44
ALOX15 P16050 3/20 0.44
CASP1 P29466 3/20 0.44
BLM P54132 3/20 0.44
CASP7 P55210 3/20 0.44
KMT2A Q03164 3/20 0.44
HSD17B10 Q99714 3/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
KDM4E B2RXH2 2/20 0.44
HPGD P15428 2/20 0.44
PTPN7 P35236 2/20 0.44
RECQL P46063 2/20 0.44
TDP1 Q9NUW8 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2905034 0.81 TDP1 (0.49) ADORA2AADORA1DHFRMEN1ALDH1A1
SCHEMBL2910349 0.73 ADORA2A (0.54) ADORA2AADORA1DHFRMEN1ALDH1A1
SCHEMBL7262230 0.71 ADORA2A (0.58) ADORA2AADORA1DHFRMEN1ALDH1A1
SCHEMBL13322063 0.71 ADORA2A (0.61) ADORA2AADORA1DHFRMEN1ALDH1A1
SCHEMBL4459534 0.71 ADORA2A (1.00) ADORA2AADORA1DHFRMEN1ALDH1A1
SCHEMBL13668449 0.69 ADORA2A (1.00) ADORA2AADORA1DHFRMEN1ALDH1A1
SCHEMBL6948083 0.68 ADORA2A (0.63) ADORA2AADORA1DHFRMEN1ALDH1A1
SCHEMBL5453909 0.68 DHFR (0.51) ADORA2AADORA1DHFRMEN1ALDH1A1
SCHEMBL4052390 0.68 ADORA2A (0.60) ADORA2AADORA1DHFRADORA2B
SCHEMBL1553903 0.67 ADORA2A (0.60) ADORA2AADORA1DHFRMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1975256-B1 Modified oligonucleotides for mismatch discrimination EPOCH BIOSCIENCES INC (US) 2012-07-11 EP disclosed
EP-1261616-B1 MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION EPOCH BIOSCIENCES INC (US) 2010-08-18 EP disclosed
EP-1261616-B1 MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION EPOCH BIOSCIENCES INC (US) 2010-08-18 EP disclosed
US-7751982-B2 TM leveling methods ELITECH HOLDING B.V. (NL) 2010-07-06 US disclosed
US-7751982-B2 TM leveling methods ELITECH HOLDING B.V. (NL) 2010-07-06 US disclosed
US-7751982-B2 TM leveling methods ELITECH HOLDING B.V. (NL) 2010-07-06 US disclosed
US-7715989-B2 Systems and methods for predicting oligonucleotide melting temperature (TmS) ELITECH HOLDING B.V. (NL) 2010-05-11 US disclosed
US-7715989-B2 Systems and methods for predicting oligonucleotide melting temperature (TmS) ELITECH HOLDING B.V. (NL) 2010-05-11 US disclosed
US-7715989-B2 Systems and methods for predicting oligonucleotide melting temperature (TmS) ELITECH HOLDING B.V. (NL) 2010-05-11 US disclosed
EP-1995330-A1 Modified oligonucleotides for mismatch discrimination Epoch Biosciences, Inc. (US) 2008-11-26 EP disclosed
US-20060003349-A1 Tm leveling compositions EPOCH BIOSCIENCES, INC. (US) 2006-01-05 US disclosed
US-6949367-B1 Modified oligonucleotides for mismatch discrimination EPOCH PHARMACEUTICALS, INC. (US) 2005-09-27 US disclosed
EP-1537488-A2 SYSTEMS AND METHODS FOR PREDICTING OLIGONUCLEOTIDE MELTING TEMPERATURES (TMS) Epoch Biosciences, Inc. (US) 2005-06-08 EP disclosed
US-20050075491-A1 TM leveling methods EPOCH BIOSCIENCES, INC. (US) 2005-04-07 US disclosed
US-6683173-B2 CONJUGATING OLIGONUCLEOTIDE WITH 3-SUBSTITUTED PYRAZOLO(3,4-D)PYRIMIDINES AND/OR 5-SUBSTITUTED PYRIMIDINE MINOR GROOVE BINDER EPOCH BIOSCIENCES, INC. 2004-01-27 US disclosed
US-20030235822-A1 Systems and methods for predicting oligonucleotide melting temperature (TmS) EPOCH BIOSCIENCES, INC. 2003-12-25 US disclosed
WO-2003107144-A2 SYSTEMS AND METHODS FOR PREDICTING OLIGONUCLEOTIDE MELTING TEMPERATURES (TMS) EPOCH BIOSCIENCES, INC. (US) 2003-12-24 WO disclosed
US-20030224359-A1 TMLEVELING METHODS EPOCH BIOSCIENCES, INC. 2003-12-04 US disclosed
EP-1261616-A2 MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION Epoch Biosciences, Inc. (US) 2002-12-04 EP disclosed
WO-2001064958-A2 MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION EPOCH BIOSCIENECS, INC. (US) 2001-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060003349-A1 Tm leveling compositions RNGTT, TYMS, NT5C3B ADORA2A 449/4885ADORA1 782/4885DHFR 586/4885
US-20050075491-A1 TM leveling methods RNGTT, TYMS, NT5C3B ADORA2A 529/4885ADORA1 1070/4885DHFR 465/4885
US-20030224359-A1 TMLEVELING METHODS PTBP3, RNGTT, DTYMK ADORA2A 687/4885ADORA1 1214/4885DHFR 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.